Q-omics provides the consensus-scored ANKHD1-EIF4EBP3 profile across patient tissues and cancer cell-line models. ANKHD1-EIF4EBP3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANKHD1-EIF4EBP3 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ANKHD1-EIF4EBP3 RNA expression shows 19,047 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where ANKHD1-EIF4EBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKHD1-EIF4EBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKHD1-EIF4EBP3 survival associations across molecular data types. ANKHD1-EIF4EBP3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKHD1-EIF4EBP3 RNA expression–survival associations across cancer types. High ANKHD1-EIF4EBP3 expression shows unfavorable associations in UVM, LIHC and ESCA, but favorable associations in MESO, PAAD and DLBC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANKHD1-EIF4EBP3 RNA expression.
This table summarizes ANKHD1-EIF4EBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ANKHD1-EIF4EBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKHD1-EIF4EBP3 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC, LIHC, CHOL and PRAD. The KIRC box plot shows higher ANKHD1-EIF4EBP3 RNA expression in tumor versus normal tissue (log2 FC = +0.348, t-test p < 0.001).
This table shows molecular features associated with ANKHD1-EIF4EBP3 in patient tissues and cancer cell lines. In patient samples, ANKHD1-EIF4EBP3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKHD1-EIF4EBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
